Its promotion of inflammation and apoptosis in the context of ischemic stroke [82,88,99,104], Parkinson’s disease [108,115], and Alzheimer’s disease [98], among many other previously discussed diseases, highlights the potential of GAS5 inhibition to be used as a therapeutic strategy to mitigate inflammation, neuronal apoptosis, and disease progression. Here, GAS5 is linked to early-onset autosomal dominant Alzheimer disease.